Roche Inks Potential $900 Million+ Deal with HOOPIKA for Multi-KRAS Mutation Approach

Retrieved on: 2022-10-21 15:16:27

Tags for this article:

Click the tags to see associated articles and topics

Roche Inks Potential $900 Million+ Deal with HOOPIKA for Multi-KRAS Mutation Approach. View article details on hiswai:

Excerpt

HOOKIPA Pharma has a strategic collaboration with Roche to develop its HB-700 immunotherapy for KRAS-mutated cancers.

Article found on: www.insideprecisionmedicine.com